Shanghai Fosun Pharmaceutical Group Co Ltd 2024 SR
The report highlights Fosun Pharma's 30-year journey as a global innovation-driven healthcare group. In 2024, the company maintained steady growth while achieving an A MSCI ESG rating. Key milestones include the launch of the first CAR-T cell therapy payment plan in China and the WHO prequalification of its second-generation artesunate injection. Environmentally, the Group reduced carbon emission intensity by 12% compared to 2020 and increased solar power generation fourfold. Socially, the Rural Doctor Project has supported 24,000 rural doctors, benefiting 3 million rural families.
Company: Shanghai Fosun Pharmaceutical Group Co Ltd
Sector: Health Care
Country: China
Year: 2024
Type: SR
Pages: 172
Shanghai Fosun Pharmaceutical Group Co Ltd
ESG And Sustainability Report
The report highlights Fosun Pharma's 30-year journey as a global innovation-driven healthcare group. In 2024, the company maintained steady growth while achieving an A MSCI ESG rating. Key milestones include the launch of the first CAR-T cell therapy payment plan in China and the WHO prequalification of its second-generation artesunate injection. Environmentally, the Group reduced carbon emission intensity by 12% compared to 2020 and increased solar power generation fourfold. Socially, the Rural Doctor Project has supported 24,000 rural doctors, benefiting 3 million rural families.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Net Zero Target
Employees